The iDose TR demonstrated sustained IOP reduction at 36 months, according to a press release from Glaukos.
The multicenter, randomized, double-masked, phase 2b clinical trial enrolled 154 patients. Fifty-one patients received fast-release iDose TR (sustained-release travoprost implant), 54 received slow-release iDose TR, and 49 received timolol twice daily. The primary efficacy endpoint was noninferiority compared with timolol following a single iDose TR administration.
Seventy percent of patients in the fast-release arm and 68% of patients in the slow-release arm were well controlled at 36